Search Page

1

Cite

Share

Engineering CAR-T Cells for Next-Generation Cancer Therapy.

Hong M, Clubb JD, Chen YY. Hong M, et al. Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30. Cancer Cell. 2020. PMID: 32735779 Free article. Review.

Cite

Share

2

Cite

Share

TCR Signaling: Mechanisms of Initiation and Propagation.

Courtney AH, Lo WL, Weiss A. Courtney AH, et al. Trends Biochem Sci. 2018 Feb;43(2):108-123. doi: 10.1016/j.tibs.2017.11.008. Epub 2017 Dec 18. Trends Biochem Sci. 2018. PMID: 29269020 Free PMC article. Review.

Cite

Share

3

Cite

Share

Mechanisms underlying T cell ageing.

Goronzy JJ, Weyand CM. Goronzy JJ, et al. Nat Rev Immunol. 2019 Sep;19(9):573-583. doi: 10.1038/s41577-019-0180-1. Epub 2019 Jun 11. Nat Rev Immunol. 2019. PMID: 31186548 Free PMC article. Review.

Cite

Share

4

Cite

Share

CAR-macrophage: A new immunotherapy candidate against solid tumors.

Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, Han D, Hong W, Wei W, Tu J. Chen Y, et al. Biomed Pharmacother. 2021 Jul;139:111605. doi: 10.1016/j.biopha.2021.111605. Epub 2021 Apr 23. Biomed Pharmacother. 2021. PMID: 33901872 Free article. Review.

Cite

Share

5

Cite

Share

B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.

Haghikia A, Schett G, Mougiakakos D. Haghikia A, et al. Lancet Neurol. 2024 Jun;23(6):615-624. doi: 10.1016/S1474-4422(24)00140-6. Lancet Neurol. 2024. PMID: 38760099 Free article. Review.

Cite

Share

6

Cite

Share

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

Wagner J, Wickman E, DeRenzo C, Gottschalk S. Wagner J, et al. Mol Ther. 2020 Nov 4;28(11):2320-2339. doi: 10.1016/j.ymthe.2020.09.015. Epub 2020 Sep 16. Mol Ther. 2020. PMID: 32979309 Free PMC article. Review.

Cite

Share

7

Cite

Share

CAR T cell combination therapies to treat cancer.

Uslu U, Castelli S, June CH. Uslu U, et al. Cancer Cell. 2024 Aug 12;42(8):1319-1325. doi: 10.1016/j.ccell.2024.07.002. Epub 2024 Jul 25. Cancer Cell. 2024. PMID: 39059390 Review.

Cite

Share

8

Cite

Share

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.

Sheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R, Gersuk V, Riddell SR, Maloney DG, Wohlfahrt ME, Pande D, Enstrom MR, Kiem HP, Adair JE, Gottardo R, Linsley PS, Turtle CJ. Sheih A, et al. Nat Commun. 2020 Jan 10;11(1):219. doi: 10.1038/s41467-019-13880-1. Nat Commun. 2020. PMID: 31924795 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.

Mog BJ, Marcou N, DiNapoli SR, Pearlman AH, Nichakawade TD, Hwang MS, Douglass J, Hsiue EH, Glavaris S, Wright KM, Konig MF, Paul S, Wyhs N, Ge J, Miller MS, Azurmendi P, Watson E, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Mog BJ, et al. Sci Transl Med. 2024 Jul 10;16(755):eadg7123. doi: 10.1126/scitranslmed.adg7123. Epub 2024 Jul 10. Sci Transl Med. 2024. PMID: 38985855

Cite

Share

10

Cite

Share

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.

Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. Lin Y, et al. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. Epub 2024 May 28. Lancet Oncol. 2024. PMID: 38821074 Review.

Cite

Share